STAAR Surgical Bundle
Who Really Controls STAAR Surgical?
Uncover the ownership secrets of STAAR Surgical Company, a leader in vision correction technology. Understanding who owns STAAR Surgical is crucial for investors and anyone tracking the ophthalmic market. From its 1983 IPO to its current market position, the ownership structure has significantly shaped its trajectory.
Founded in 1982, STAAR Surgical Company has evolved from a private entity to a publicly traded enterprise, impacting its strategic direction and investor relations. This analysis will explore the dynamic landscape of STAAR Surgical SWOT Analysis, examining its major shareholders, insider ownership, and the influence of its Board of Directors. Knowing who owns STAAR Surgical provides critical insights into the company's financial performance and future prospects, impacting decisions related to STAAR Surgical stock.
Who Founded STAAR Surgical?
The story of the company began in 1982. While the exact details of the founders' backgrounds and initial investments aren't readily available, the company's journey to public trading in 1983 marked a significant change in its ownership structure. Before the initial public offering (IPO), ownership was likely concentrated among the founders and any early investors.
The IPO in 1983 was a pivotal moment. It opened the door for public investment, shifting from a privately held structure to one with a broader base of shareholders. This transition allowed for increased capital and a wider investor pool, influencing the company's growth trajectory.
The shift to being publicly traded involved distributing shares to a larger group of investors. Although the initial market capitalization isn't specified in the available information, the IPO signaled a move towards greater transparency and accountability, typical of publicly listed companies.
Founders and Early Ownership
The company was founded in 1982, with the IPO occurring in 1983. The early ownership was primarily held by the founders and initial investors.
IPO Impact
The IPO opened the company to public investment, broadening its shareholder base. This transition allowed for increased capital and a wider investor pool, influencing the company's growth trajectory.
Ownership Transition
The IPO involved distributing shares to a broader investor base. This shift marked a move towards greater transparency and accountability.
Early Investors
Before the IPO, the ownership was concentrated among the founders and any early backers or angel investors who provided initial capital.
Public Offering
The public offering marked a significant shift in its ownership structure, opening it up to public investment.
Market Capitalization
The initial market capitalization at the time of the IPO is not specified in the provided information.
Understanding the early ownership of the company is crucial for investors looking at the company's history. The shift from private to public ownership, as detailed in the Brief History of STAAR Surgical, is a key aspect of its financial journey. The initial shareholders, likely including the founders and early investors, played a vital role in setting the stage for the company's growth. Today, to understand the current ownership structure, investors often look at factors like the company's stock, major shareholders, and the overall market capitalization. The company's financial performance and annual reports provide insights into the current state of the company, including details on who owns the company and how it has evolved since its early days. For those interested in investing, information on how to buy the company's stock and the company's investor relations can be found through various financial resources.
Key Takeaways
Early ownership of the company was concentrated among founders and early investors before the IPO.
- The IPO in 1983 marked a transition to public ownership.
- The initial market capitalization at the time of the IPO is not specified.
- Understanding the company's history is crucial for investors.
- Today, investors can find information on the company's stock, major shareholders, and financial performance.
STAAR Surgical SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has STAAR Surgical’s Ownership Changed Over Time?
The evolution of ownership in STAAR Surgical Company has been shaped by its journey since becoming a publicly traded entity in 1983. The ownership structure reflects a blend of institutional investors, company insiders, and individual shareholders. The company's market capitalization and outstanding shares provide a snapshot of its current valuation and ownership distribution, which is essential for understanding the dynamics of the company's stock.
As of June 2025, the market capitalization of STAAR Surgical is approximately $865 million, with 49.5 million shares outstanding. The ownership is distributed among institutional investors (approximately 48.21%), insiders (around 44.52%), and public companies and individual investors (about 7.27%). This distribution highlights the influence of institutional investors and the significant stake held by company insiders.
| Ownership Category | Approximate Percentage | Notes |
|---|---|---|
| Institutional Investors | 48.21% | Includes a diverse group of investment firms. |
| Insiders | 44.52% | Comprises company executives and board members. |
| Public Companies and Individual Investors | 7.27% | Represents the remaining ownership. |
Institutional investors play a crucial role in shaping the company's strategy and governance. As of March 31, 2025, there were 436 institutional owners and shareholders, collectively holding 60,812,274 shares. Broadwood Capital Inc. is a significant stakeholder, holding 12,455,264 shares as of March 31, 2025, which represents approximately 25.149% of the company's ownership. BlackRock, Inc. holds 8,039,145 shares with sole voting power as of December 31, 2024. Vanguard Group Inc. holds 5,415,710 shares as of March 31, 2025. These holdings demonstrate the significant influence these institutions have on the company. For more information on the company's target market, consider reading this article about the Target Market of STAAR Surgical.
Key Takeaways on STAAR Surgical Ownership
STAAR Surgical's ownership is a mix of institutional investors, insiders, and individual shareholders.
- Institutional investors hold a significant portion of the stock, influencing company strategy.
- Insider ownership, though smaller, reflects the commitment of company leadership.
- Understanding the ownership structure is crucial for investors analyzing the company's future.
- The company's market capitalization is approximately $865 million as of June 2025.
STAAR Surgical PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on STAAR Surgical’s Board?
As of April 24, 2025, the Board of Directors for the STAAR Surgical company consists of seven members. The board includes Arthur C. Butcher, Stephen C. Farrell, Wei Jiang, Louis E. Silverman, Aimee S. Weisner, Elizabeth Yeu, M.D., and Lilian Y. Zhou. Stephen C. Farrell, who is also the CEO, and Wei Jiang, serving as a special strategic advisor for the Asia Pacific business through the end of fiscal year 2025, do not qualify as independent directors under Nasdaq rules. Louis E. Silverman rejoined the board on April 24, 2025, after previously serving from 2014-2022. Aimee S. Weisner will not stand for re-election at the June 2025 annual meeting.
The remaining five directors are considered independent under SEC and Nasdaq rules. Understanding the composition of the board is vital for STAAR Surgical investors and anyone interested in STAAR Surgical ownership, as it influences strategic decisions and company oversight. The board's structure and the independence of its members are key factors in corporate governance and investor confidence. This information is crucial for those tracking the STAAR Surgical stock and evaluating the company's direction.
| Director | Role | Independence Status |
|---|---|---|
| Arthur C. Butcher | Director | Independent |
| Stephen C. Farrell | CEO & Director | Non-Independent |
| Wei Jiang | Director & Special Strategic Advisor | Non-Independent |
| Louis E. Silverman | Director | Independent |
| Aimee S. Weisner | Director | Independent |
| Elizabeth Yeu, M.D. | Director | Independent |
| Lilian Y. Zhou | Director | Independent |
The voting structure at STAAR Surgical Company is straightforward: one share equals one vote. This means that shareholders can vote on company matters based on the number of shares they own. The company's charter does not allow for cumulative voting, so the individuals who receive the most votes are elected as directors. For more insights into the company's operations, consider reading about the Revenue Streams & Business Model of STAAR Surgical.
Key Takeaways on STAAR Surgical's Governance
The board is composed of seven directors, with a mix of independent and non-independent members. Understanding the voting structure is essential for STAAR Surgical investors. This information is crucial for anyone looking into STAAR Surgical owner details.
- The CEO, Stephen C. Farrell, is also a board member.
- Wei Jiang serves as a special strategic advisor.
- Louis E. Silverman rejoined the board in April 2025.
- Aimee S. Weisner will not seek re-election in June 2025.
STAAR Surgical Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped STAAR Surgical’s Ownership Landscape?
Over the past few years, significant developments have shaped the ownership landscape of the STAAR Surgical company. In May 2025, the Board of Directors approved a share repurchase program, authorizing up to $30 million for repurchasing outstanding common stock. This move reflects management's confidence in the company's value and its commitment to rewarding shareholders. Moreover, the company has experienced shifts in its leadership team, including Louis E. Silverman rejoining the Board of Directors in April 2025, and Wei Jiang transitioning to a strategic advisory role for the Asia Pacific business.
Institutional investors continue to hold a dominant position in STAAR Surgical. As of May 2025, institutional ownership remained largely stable at 106.95%. Insider holdings saw a slight decrease, from 0.65% to 0.64%. These figures highlight the ongoing strong institutional interest in the company. The company's financial performance in 2024 showed total net sales of $313.9 million, a 3% decrease from $322.4 million in 2023, largely due to macroeconomic conditions in China. Despite these challenges, excluding China, the company projects ICL sales to grow between 9% and 15% for fiscal year 2025, reaching approximately $165 million to $175 million. For further insights, you can explore the Marketing Strategy of STAAR Surgical.
| Metric | Value | Year |
|---|---|---|
| Institutional Ownership | 106.95% | May 2025 |
| Insider Holdings | 0.64% | May 2025 |
| Total Net Sales | $313.9 million | 2024 |
The company has withdrawn its financial outlook for 2025 due to economic uncertainties, but remains committed to transparency. STAAR Surgical aims to increase its market share in the US, with potential for significant sales growth if it achieves market penetration comparable to other major markets. To support this, the company plans to accelerate ICL production in Switzerland to supplement U.S. manufacturing capacity and mitigate potential tariff impacts.
Share Repurchase Program
The Board of Directors authorized a share repurchase program of up to $30 million of its outstanding common stock in May 2025.
Leadership Changes
Louis E. Silverman rejoined the Board of Directors in April 2025. Wei Jiang transitioned to a special strategic advisor role.
Financial Performance
Total net sales for fiscal year 2024 were $313.9 million, a 3% decrease compared to 2023.
Future Outlook
The company projects ICL sales excluding China to grow between 9% and 15% for fiscal year 2025.
STAAR Surgical Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of STAAR Surgical Company?
- What is Competitive Landscape of STAAR Surgical Company?
- What is Growth Strategy and Future Prospects of STAAR Surgical Company?
- How Does STAAR Surgical Company Work?
- What is Sales and Marketing Strategy of STAAR Surgical Company?
- What is Brief History of STAAR Surgical Company?
- What is Customer Demographics and Target Market of STAAR Surgical Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.